The Future of Biomarkers in EGFR-Mutant NSCLC: Sequencing Strategies and Optimizing Patient Time on Treatment

Video content above is prompted by the following:

Optimizing Treatment Sequencing

Key Themes:

• Local Therapy: Role of stereotactic body radiation therapy (SBRT) for oligoprogressive disease
• Maintenance Strategies: Questions about optimal duration of chemotherapy maintenance and amivantamab treatment
• Treatment Sequencing: Impact of first-line therapy selection on subsequent options

Notable Insights:

• Dr Dietrich: Supports local treatment for oligoprogressive disease, stating “depending on the patient in my practice, up to 6 sites are reasonable” for SBRT treatment. He believes “the impact of amivantamab or chemotherapy respectively is best when EGFR disease is sensitized by a third-generation EGFR [tyrosine kinase inhibitor] backbone.”
• Dr Piotrowska: Expressed concern about biomarker-directed therapy, noting “we’ve taken a step back from that” with combination approaches where “we really don’t know which patients are likely to benefit from each.” She emphasized the need for better biomarkers to guide both frontline and later-line therapy selection.